Donor fat-derived stem cells for diabetic foot ulcers
Tests stem cells from donated fat tissue for diabetic foot ulcers in adults.
Key facts
- Who runs it
- Medical University of Warsaw
- Where
- Poland2 sites in 1 countryChoose a country to see its sites
- Registry title
- Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot Syndrome.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 105 people, planned
- Started
- 5 Mar 2025
- Expected to end
- 1 Aug 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Allogeneic ADSC/ASC (alloADSC-DFU-RL)
- Placebo (PL-DFU-RL)
- Record updated
- 26 October 2026
Who can take part
The trial is looking for adults with diabetes who have a foot ulcer (diabetic foot syndrome) that has lasted at least 6 weeks. It tests donor fat-derived stem cells against placebo.
- Age
- 18 years and older
- Sex
- All
- Disease stage
- Neuropathic and/or neuroischemic diabetic foot ulcer, grade IA/IIA or IC/IIC by the University of Texas classification. The wound is 1-25 cm2 after cleaning, with enough blood flow (oxygen pressure not less than 30 mmHg or foot artery pressure not less than 50 mmHg). Ulcer present for at least 6 weeks.
- Earlier treatment
- No revascularisation (procedure to restore blood flow) in the affected leg within 3 months, and none planned. No oral or intravenous antibiotics at enrolment. No immunosuppressive treatment, including systemic corticosteroids, within 30 days. No allergy immunotherapy within 30 days.
- Biomarker or test result
- HbA1c no more than 11% (97 mmol/mol).
- Main reasons for not taking part
- Active infection in the wound, or bone infection (osteitis or osteomyelitis)
- Serious lack of blood flow to the leg, or active Charcot joint
- Chronic kidney disease with GFR < 20 ml/min
- Pregnancy or breastfeeding
- Active cancer or cancer in the last 5 years, except local tumors not involving the foot
Show the full registry criteria (35)Hide the full registry criteria
Who can take part
- Age ≥ 18 years at the time of consent
- The patient's psychophysical and legal ability to give informed consent to participate in the study,
- Signing the informed consent document for participation in the study,
- A confirmed diagnosis of type 1 diabetes, type 2 diabetes, LADA, MODY, or other types of diabetes, documented in accordance with current diagnostic criteria
- Ulcer classified as diabetic foot syndrome (DFS) of neuropathic and/or neuroischemic etiology corresponding to grade IA/IIA and IC/IIC according to the University of Texas classification (Appendix E),
- A period of not less than 6 weeks since the onset of the ulceration,
- Presence of a wound of 1-25 cm2 (after wound debridement),
- Satisfactory blood supply to the wound area (assessed by transcutaneous measurement of oxygen partial pressure, if not less than 30 mmHg, or measurement of systolic arterial pressure on the posterior tibial and/or dorsal artery of the foot, which will not be less than 50 mmHg) to exclude patients who require revascularisation therapy
- A glycated haemoglobin value (HbA1c) of no more than 11%,
- General health status of the patient that, in the opinion of the investigator, allows participation in all study procedures,
- Use of a form of wound relief recommended by the Investigator,
- In the case of women of childbearing potential, agreement to use of methods of effective contraception to avoid pregnancy and/or based on the following criteria: - a woman who is incapable of having offspring (after hysterectomy or bilateral ovarian resection or after menopause, defined as a period of at least 12 months since the last menstrual period) is exempt from pregnancy testing - a woman capable of having offspring with a negative pregnancy test result prior to the first day dose of the study product and who agrees to cycle pregnancy tests according to the study protocol and to use appropriate contraception until one month after the end of the active phase of the study (up to V6), or 2 months after the last administration of the study drug. For men - fertile men who are sexually active with a partner who may become pregnant are required to use a barrier method throughout the entire duration of the study, and the partners of study participants (who are capable of bearing children) are required to use the same contraceptive methods as female study participants until Visit V6
Who cannot take part
- Revascularisation procedure in the affected lower limb within less than 3 months prior to study inclusion or planned revascularisation procedure,
- Oral/intravenous antibiotic therapy at the time of inclusion in the study,
- A patient undergoing immunosuppressive therapy, including systemic corticosteroid therapy (within 30 days prior to study inclusion). Topical corticosteroid therapy does not constitute an exclusion criterion
- Patients undergoing immunotherapy for allergic diseases (within 30 days prior to the screening visit -calculated from the last dose of such therapy) or those planning to initiate or resume such therapy during the clinical trial,
- Etiology of the ulcer other than diabetic foot syndrome,
- Presence of active infection in the wound at the time of inclusion in the study,
- Allergy to thrombin,
- Active venous thrombosis,
- Systemic diseases in the exacerbation stage (acute or decompensated), including heart, kidney, and liver diseases,
- Active alcoholic disease or psychoactive drug addiction,
- Allergies to dressing materials used in the study,
- Active cancerous process or cancer in the last 5 years, excluding locally malignant tumors that do not involve the tissues of the foot
- Presence of a clinically known active, uncontrolled infection, e.g., Hepatitis B, Hepatitis C, HIV, and venereal disease (syphilis),
- Chronic kidney disease with GFR < 20 ml/min,
- Significant features of malnutrition further impairing the healing process, regardless of the cause (albumin < 2.5 g/dL and total protein < 5g/dL),
- Hemoglobin concentration < 9g/dL,
- Serum transaminase activity (alanine and aspartate) exceeding 3x the upper limit of normal (local)
- Wound area <1 cm² or >25 cm²,
- Patient was eligible to participate in another clinical trial in the 4 weeks preceding study eligibility
- Clinically significant limb ischaemia (assessed by transcutaneous measurement of oxygen partial pressure if less than 30 mmHg or measurement of systolic arterial pressure on the posterior tibial and dorsal artery of the foot which is less than 50 mmHg)
- Presence of an active phase of Charcot joint,
- Osteitis and/or osteomyelitis, including cases assessed using a positive probe-to-bone test,
- Pregnancy and lactation,
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Diabetic foot ulcer
This trial is currently available in Poland.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this study is to evaluate the safety and efficacy of an advanced therapy medicinal product containing live allogeneic adipose-derived mesenchymal stem cells (ADSC/ASC) for the treatment of diabetic foot ulcers in a randomized, double-blind, three-arm study.
The 3 groups in the trial
- A - Two administrations of allogeneic ADSC/ASCTreatment being tested
Participants will receive two administrations of allogeneic ADSC/ASC, at V0 (Day 0) and V2 (Day 14), in addition to standard-of-care (SOC) treatment for diabetic foot ulcer.
Treatment: Allogeneic ADSC/ASC (alloADSC-DFU-RL)
- B - One administration of allogeneic ADSC/ASC and one administration of placeboTreatment being tested
Participants will receive allogeneic ADSC/ASC at V0 (Day 0), followed by placebo at V2 (Day 14), in addition to standard-of-care (SOC) treatment for diabetic foot ulcer.
Treatment: Allogeneic ADSC/ASC (alloADSC-DFU-RL) and Placebo (PL-DFU-RL)
- C - Two administrations of placeboPlacebo, for comparison
Participants will receive two administrations of placebo, at V0 (Day 0) and V2 (Day 14), in addition to standard-of-care (SOC) treatment for diabetic foot ulcer.
Treatment: Placebo (PL-DFU-RL)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Evaluation of the Safety and Efficacy of an Advanced Therapy Medicinal Product Containing Live ASCs in the Treatment of Diabetic Foot Syndrome - a Double-blind, Randomized Study.
- Plain-language title
- Donor fat-derived stem cells for diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06843122, who can take part
- Record updated
- 26 October 2026